Germany’s Merck has acquired Lonza’s Modular Automated Sampling Technology (MAST) platform for an undisclosed sum. The Darmstadt-based chemicals, pharmaceuticals and life...

Swiss CDMO Lonza has signed an agreement for the large-scale manufacture of the main drug intermediate for Swedish specialty pharma Oasmia’s investigational cancer drug...

Swiss CDMO Lonza has completed a planned laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China and plans to begin...

Lonza has agreed a manufacturing partnership with Australian biotech HaemaLogiX for the latter’s lead multiple myeloma drug candidate KappaMab.

Swiss CDMO Lonza has agreed a five-year collaboration on the development and manufacturing of biologics and small molecules with European venture capital firm Bioqube...

CDMO Lonza is adding microbial development capabilities at its Visp, Switzerland, site. The company said the investment will support a capacity increase services...

Swiss specialty chemicals producer Arxada, which was recently sold by CDMO Lonza to private equity funds Bain Capital and Cinven, has made its first strategic move since...

Swiss CDMO Lonza is making major strides to expand its position in exosome manufacturing. This week it announced two new moves. In the first, it will acquire and operate...